1. The economics of HIV in Africa [editorial]. Lancet 2002: 360;1.

2. UNAIDS. AIDS epidemic update: December 2001. Available at epidemicpupdate/reportpdec01/index.html (accessed June 2002).

3. Centers for Disease Control and Prevention, Divisions of HIV/AIDS Prevention. Human immunodeficiency virus type 2. Available at (accessed June 2002).

4. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 2000;283: 2653-2654.

5. Office of Communications and Public Liaison, National Institute of Allergy and Infectious Diseases. Fact Sheet. Bethesda, MD: National Institutes of Health; May 2001.

6. The National Institute of Allergy and Infectious Diseases (March 1999). Available at http://www.maid. (accessed June 2002).

7. Centers for Disease Control and Prevention. HIV/AIDS surveillance report.1999;11: 1-44.

8. Dasgupta A, Okhuysen PC. Pharmacokinetic and other drug interactions in patients with AIDS. Ther Drug Monit 2001;23: 591-605.

9. van Heeswick RPG. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther Drug Monit 2002;24: 323-331.

10. Soldin OP, Soldin SJ. Therapeutic drug monitoring in pediatrics. Ther Drug Monit 2002;24: 1-8.

11. Gerber JG. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin Infect Dis 2000;30(Suppl 2): S123-S129.

12. Back DJ, Khoo SH, Gibbons SE, et al. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. Ther Drug Monit 2000;22: 122-126.

13. Merry C. Therapeutic drug monitoring of antiretroviral drugs. Northwest Univ Rep HIV/AIDS 2000;4: 1-8.

14. van Heeswick RPG, Veldkamp AI, Mulder JW, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000;14: F77-F82.

15. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV infected patients treated with genotypic-guided therapy: pharmacological data from the Viradept study. AIDS 2000;14: 1333-1339.

16. Burger D, Hugen P, Droste J, et al. Therapeutic drug monitoring (TDM) of nelfinavir (NFV) and indinavir (IDV) in treatment-naive patients improves therapeutic outcome after 1 year: results from ATHENA. In: Abstracts of the First IAS Conference on HIV Pathogenesis and Treatment; 2001; Buenos Aires, Argentina. Abstract 30.

17. Lebergeber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999;353: 863-868.

18. Erb P, Battegay M, Zimmerli W, et al. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort: Swiss Cohort Study. Arch Intern Med 2000;160: 1134-1140.

19. Junghans C, Low N, Chan P, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999;13: 2547-2554.

20. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk of virologic failure and adverse drug reactions. Ann Intern Med 1999;131: 81-87.

21. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001;15: 1089-1095.

22. Hoetelmans RMW, Reijers MHE, Weverling GJ, et al. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998;12: F111-F115.

23. Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side effects: implications for therapeutic drug monitoring. AIDS 1999;13: 2083-2089.

24. Sadler BM, Gillotin C, Lou C, et al. Pharmacokinetic and pharmacodynamic study of the immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001;45: 30-37.

25. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15: 71-75.

26. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002;16: 551-560.

27. Anderson PL, Fletcher CV. Clinical pharmacologic considerations for HIV-1 protease inhibitors. Curr Infect Dis Rep 2001;3: 381-387.

28. Fletcher CV, Balfour HH Jr. Variability in zidovudine serum concentrations. Pharmacotherapy 1996;16: 1154-1158.

29. Barry MG, Merry C, Lloyd J, et al. Variability in trough plasma saquinavir concentrations in HIV case for therapeutic drug monitoring. Br J Clin Pharmacol 1998;45: 501-502.

30. Moyer TP, Temesgen Z, Enger R, et al. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem 1999;45: 1465-1476.

31. Titier K, Lagrange F, Pehourcq F, et al. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. Ther Drug Monit 2002;24: 417-424.

32. Villani P, Feroggio M, Gianelli L, et al. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid highperformance liquid chromatography-mass spectrometry assay. Ther Drug Monit 2002;24: 380-388.

33. Volosov A, Alexander C, Ting L, Soldin SJ. Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry. Clin Biochem 2002;35: 99-103.

34. Ghoshal AK, Soldin SJ. Improved method for concurrent quantification of antiretrovirals by liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2003;25: 541-543.

35. Soldin SJ, Rakhmanina NY, Spiegel HML, Sever JL. Therapeutic drug monitoring for patients with HIV infection: Children's National Medical Center, Washington, DC Experience. Ther Drug Monit 2004;26: 107-109.

36. Rakhmanina NY, Cappardli EV, Van den Pocker JN, Williams K, Sever JL, Spiegel HML and Soldin SJ. Nevirapine Concentration in Nonstimulated Saliva: An Alternative to Plasma Sampling in Children with Human. Immunodeficiency Virus Infection. Ther Drug Monit 2007: 29; 110-117.

Allergic To Everything

Allergic To Everything

The human body And Todays chemical infested world. Here is a news flash You are not allergic to pollen, pet dander, or whatever it is that makes your body revolt Rather, your body just can not handle that one thing, what ever it is, anymore, due to the massive barrage of toxic chemicals you and everyone else are ingesting every single day.

Get My Free Audio and Ebook

Post a comment